\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={Association between Systemic Lupus Erythematosus and Refractory Ulcerative Colitis: What are our Therapeutic Options?}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{1970-01-01 (revised: 01 January 1970)} \def\TheID{\makeatother } \def\TheDate{1970-01-01} \title{Association between Systemic Lupus Erythematosus and Refractory Ulcerative Colitis: What are our Therapeutic Options?} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{Yassine Chait} \author[2]{Nacir Oussama} \author[3]{Ait Errami Adil} \author[4]{Samlani Zouhour} \author[5]{Krati Khadija} \author[6]{Oubaha Sofia} \renewcommand\Authands{ and } \date{\small \em Received: 1 January 1970 Accepted: 1 January 1970 Published: 1 January 1970} \maketitle \begin{abstract} Systemic lupus erythematosus (SLE)is an autoimmune disease in which the immune system through antibodies attacks its own tissues, and causes inflammation and tissue damage in the affected organs. It can affect the skin, brain, lungs, kidneys, and blood vessels (1).Ulcerative colitis is an inflammatory bowel disease (IBD) that causes inflammation and ulcers (sores) in your digestive tract. Ulcerative colitis affects the innermost lining of your large intestine, also called the colon, and rectum.This article is about a patient followed for systemic lupus, presenting digest if symptoms reveling ulcerative colitis, the therapeutic challenge we faced is the potential aggravation of lupus symptoms under anti TNF therapy. The patient underwent curative surgery without major complication. \end{abstract} \keywords{} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \begin{textblock*}{10cm}(1.05cm,3cm) {{\textit{CrossRef DOI of original article:}} \underline{}} \end{textblock*}\let\tabcellsep& \section[{Introduction}]{Introduction}\par atient with systemic lupus erythematosus (SLE) may experience various intestinal disorders such as diarrhea, vomiting, rectal bleeding, tenesmus. However, even if it's not very common, it is important to think of inflammatory bowel diseases especially Crohn's disease as well as Ulcerative colitis. In fact, SLE and Ulcerative colitis (UC)rarely coexist. They may both have intestinal manifestations, laboratory results, and radiographic findings that appear similar, therefore differentiating between intestinal involvement in UC and in SLE may be difficult \hyperref[b0]{(1)}.\par Moreover, there are issues establishing true links between UC and SLE because SLE may mimic UC, and some UC treatments may cause drug induced SLE \hyperref[b0]{(1)}.\par This makes the diagnosis of both diseases in one patient a real challenge. There are, in fact, few reports suggesting an association between these diseases \hyperref[b0]{(1)}\hyperref[b1]{(2)}\hyperref[b2]{(3)}\hyperref[b3]{(4)}\hyperref[b4]{(5)}\hyperref[b5]{(6)}.\par Current understanding of the pathogenesis of the UC and SLE suggests that immune mechanisms play a prominent role in both diseases. In both diseases, genetic seems also to play an important role. Genetic markers located in the short arm of chromosome 6 have been found associated with both SLE to a lesser degree with UC \hyperref[b6]{(7,}\hyperref[b7]{8)}.\par It is well known that UC is a chronic condition for which therapy is required to induce and maintain remission; therapeutic decisions should be categorized into those for induction and maintenance, with a goal of obtaining and maintaining a steroid-free remission \hyperref[b8]{(9)}.\par Ulcerative colitis can be treated by 5aminosalicylate (5-ASA), steroids oranti tumor necrosis factor alpha (anti-TNF alpha). SLE is known to interfere with some of these treatments, moreover, it can be a complication of these treatments. All this poses a real problematic while managing some UC cases, especially those with resistant to the majority of medical treatments \hyperref[b8]{(9)}.\par The aim of our case report is to present one of these problematic cases, to compare it with different experiences in other centers, to review the literature in order to find out therapeutic options for these cases, and why not be a base for ulterior guidelines. \section[{II.}]{II.} \section[{Observation}]{Observation}\par At the age of 31, the patient was admitted with a seven month history official and finger erythema and arthralgia. Physical Examination revealed a typical malarrash (Figure \hyperref[fig_0]{1}) and discoid lesions on her fingers (Figure \hyperref[fig_1]{2}). The antinuclear, -antibody (ANA) were positives (1/256), the antibodies to double-stranded (DNA) were positives, the serum complement was low (17.6Vlml:normal30-40). The patient was therefore diagnosed with SLE according to American Rheumatism Association criteria for SLE. The patient began treatment with 30 mg/day prednisolone (PSL) and chloroquine 400mg/day, PSL was subsequently reduced to 10 mg/day. The symptoms were controlled in the following 9 years under treatment. The diagnostic of UC was made and treatment with PSL 50mg daily, azathioprine 125 mg/day, chloroquine 200 mg/day was begun. This was followed by significant improvement. Two months later, remission was maintained with azathioprine, PSL 10 mg/day and chloroquine.\par The patient was admitted again 6 months later, she developed bloody diarrhea with abdominal pain, and tenesumus, colonoscopy revealed inflamed hyperemic colonic mucosa with multiple active ulcers, Hemoglobin (Hb) was 9.1 g/dl (normocytic), white blood cell count was 12.44 × 103/ml (neutrophilic leukocytes: 90.8\%, lymphocytes: 7.4\%), and platelets were 3 × 105 /?l, C-reactive protein(CRP) and erythrocyte sedimentation rate were 78 mg/dl and 35 mm/h respectively. The patient was therefore treated with intravenous corticosteroids (1mg/kg/day) for 7 days then with PSL 50 mg/day, and azathioprine was switched to 6 mercaptopurine (6MP) 75mg/day, this was followed by clinical and biological improvement.\par The patient developed 3 weeks later, anemia (Hb: 7.5 g/dl) and leucopenia (white blood cell count was 2341/ml), this was related to 6MP hematotoxicity. 6 mercaptopurine (6MP) was stopped and anemia as well as leucopenia improved. The patient was then treated with methotrexate (MTX) to maintain remission. Remission was maintained for the following year under MTX.\par A year and two months later, the patient was admitted for an UC attack, she was having Bloody diarrhea as well as severe tenesmus and rectal bleeding, colonoscopy revealed inflamedfriable mucosa severely hemorrhagic. Bblood test reveled anemia with Hb: 8.4 g/dl (normocytic), white blood cell count was 15.333 x 10 3 /ml, CRP was 120 mg/dl, stool studies were negative for infection. Intravenous corticosteroids as well as corticosteroid and 5-ASA enemas were begun and the patient showed clinical and biological improvement (number of bloody diarrhea diminished as well as CRP (40 vs 120). The colitis was then considered an immunomodulator refractory colitis, and we had to consider another treatment to maintain remission.\par As the patient was treated for SLE, and due the risk of aggravating this pathology with anti-tumornecrosis-factor alpha (Anti TNF alpha), we proposed the patient for curative surgery (Colectomy with ileal pouchanal anastomosis) as an alternative to biological therapy. After explaining benefits and risks of the procedure, and after getting consent, the patient underwent surgery without major complications. She is now regularly followed up in our hospital (University hospital Mohamed VI of marrakech) for her SLE as well as the UC. \section[{Discussion}]{Discussion}\par Autoimmune diseases tend to co-exist; however, systemic lupus erythematosus (SLE) and ulcerative colitis (UC) are rarely described together and a systematic review of the medical literature has seldom been undertaken \hyperref[b9]{(10)}. As reported by several authors, the estimated prevalence of UC in SLE patients is around 0.4\% \hyperref[b10]{(11)}.\par The precise mechanisms of UC remain undetermined, but autoimmune mechanisms are supposed to be involved in the development of UC as well as InSLE. For example, anti-bodies specific to a Mr 40,000 protein found only incolonic, skin, and biliary epithelia have been demonstrated in patients with UC \hyperref[b1]{(2)}. Around 40\% of SLE patients have gastrointestinal problems, of which gastroduodenal mucosal lesions as adverse effects of nonsteroidal antiinflammatory agents, corticosteroids or cytotoxic agents are the most common. On the other hand, disease itself causes abdominal pain in only 8\% of the SLE patients \hyperref[b11]{(12)}.\par Main symptoms include abdominal pain, diarrhea, and bloody stool. The symptomatic feature is indistinguishable from that in inflammatory bowel diseases, especially ulcerative colitis \hyperref[b12]{(13)}.\par Coexistence of SLE and UC is difficult to diagnose because both diseases have several similar gastrointestinal symptoms and some drugs used to treat UC may cause drug-induced lupus particularly sulfasalazine, 5-ASA, and infliximab \hyperref[b13]{(14)}. So, it maybe difficult to differentiate whether the symptoms are due to the SLE or other diseases. In Lupuscolitis, ulceration with bleeding or perforation is caused by the inflammatory involvement of small vessels and, sometimes, by necrotizing angiitis of small arteries and venules with the deposition of circulating immune complexes \hyperref[b1]{(2)}.\par In SLE, Abdominal vascular involvement usually occurs when the disease activity in other organs increases. The evaluation of overall clinical and laboratory findings may help the differential diagnosis (2).\par In our case, SLE was considered to be inactive under chloriquine and corticosteroide at the onset of abdominal pain and bloody diarrhea, and typical histopathologic changes of UC such as amicroabscess in the crypt were found in the colo-rectal mucosa.\par UC may happen before or after the diagnosis of SLE \hyperref[b13]{(14)}. Our patient was treated for SLE 9 years before developing UC. Many authors described some differences(15)compared to SLE, UC presents more frequently as bloody diarrhea, abdominal pain, and tenesmus.\par In all cases, the diagnosis of SLE is made according to the classification criteria for SLE, which necessitate the presence of at least 4 out of 11 clinical and laboratory criteria. The diagnosis of UC is made on the basis of typical clinical, imaging, endoscopic, and histological findings \hyperref[b14]{(15)}.\par Our case problematic was related to our therapeutic options, biological therapy was normally indicated for ulcerative colitis, however, the patient was also treated for lupus, and because of the risk of aggravation of SLE after giving anti TNF alpha, we preferred reviewing our options.\par To understand the risk of anti TNF alpha induced SLE, we reviewed some cases of lupus like reaction, and DILE (drug induced erythematosus) and its pathogenesis.\par Drug-induced lupus erythematosus (DILE) is defined as a lupus-like syndrome temporally related to continuous drug exposure which resolves after discontinuation of the offending drug. There are currently no standard diagnostic criteria for DILE and the pathomechanisms are still unclear. Similarly to idiopathic lupus, DILE can be diveded into systemic (SLE), subacute cutaneous (SCLE) and chronic cutaneous lupus (CCLE). Systemic DILE is characterized by typical lupus-like symptoms including skin signs, usually mild systemic involvement and a typical laboratory profile with positive antinuclear and anti-histone antibodies, while anti-double strand (ds) DNA and anti-extractable nuclear antigens antibodies are rare \hyperref[b15]{(16)}.\par Sulphasalazine and Anti TNF alpha have been associated with DILE in several cases in the literature \hyperref[b16]{(17)}. Yet this risk of developing Lupus under anti TNF alpha is very low \hyperref[b16]{(17)}, which leads to asking if we should or not use biological therapy in patients with SLE.\par Here are some cases of DILE, in patients treated for UC.\par Griffiths and al. ( {\ref 18}) report a case of a patient who developed a lupus syndrome while receiving sulphasalazine for ulcerative colitis. They first obtained remission, then the patient developed a non-deforming arthritis with active synovitis of shoulders, wrists, metacarpophalangeal joints, proximal interphalangeal joints and digital vasculiticlesions,. Anti-nuclear antibodies (ANA) were present in high titres with a homogeneous pattern. DNA antibody concentrations were raised (190 U/ml (normal:<25 U/ml)).\par A drug-induced lupus syndrome was suspected, so sulphasalazine was stopped, cilincal conditions were then slowly resolving. Levels of DNA binding activity and ANA titres remained high for six months after sulphasalazine was stopped, but then fell to normal \hyperref[b17]{(18)}. Another study reviewed 13 cases of DILE due to infliximab in patients with inflammatory bowel diseases IBD \hyperref[b18]{(19)}. In these series of patients, DILE was a femalepreponderant disease with a female-to-male ratio of 11:2, and 5 patients were treated for ulcerative colitis \hyperref[b18]{(19)}.\par In this same series of patients, Joint manifestations dominated. Symmetric large joint arthralgias were reported by all patients. Fever and malar rash were noted in two and three out of the 13 patients, respectively. The antinuclear antibody titer was elevated in all patients with DILE, The median peak antinuclear antibody (ANA) titer was 1 in 2560, Anti-dsDNA antibodies were tested in 12 patients \hyperref[b18]{(19)}.Anti-TNF therapy was withdrawn in all patients upon diagnosis of DILE, and the resolution of joint symptoms was obtained in a median of 4 weeks (range 3-12 weeks) \hyperref[b18]{(19)}.\par In our case, the patient was already treated for SLE before developing UC, and did not receive any the DILE causative drugs.\par The following cases report the experience of treating patients with SLE as well as inflammatory bowel disease with biological therapy despite the risk early mentioned.\par Yamashita and al.( {\ref 20}) report a case of a 55year-old Japanese woman with systemic lupus erythematosus (SLE), she developed continuous gastrointestinal bleeding and diarrhea since the patient was aged 30 years that was initially treated asSLErelated colitis. The patient underwent surgery for anal fistulas twice at 50 and 54 years of age and her symptoms were atypical of lupusenteritis. Colonoscopy was performed again when the patient was 55 years of age because we suspected she hadsome type of inflammatory bowel disease (IBD). Histopathological examination revealed non-caseating granuloma and no evidence of vasculitis, consistent with crohn's disease (CD). Introduction of infliximab dramatically relieved the patient's melena and abdominal symptoms without aggravating SLE symptoms \hyperref[b19]{(20)}. {\ref 21}) report a case of CD occurred in a young woman 8 years after a diagnosis of lupus nephritis according to clinical, laboratory and histological criteria. CD was unresponsive to steroids and immunosuppressants and, therefore, the patient was treated with antitumour necrosis factor alpha monoclonal antibody (Infliximab). This therapy led to the remission of both CD (50\% of Crohn's Disease Activity Index-CDAI-decrease) and lupus nephritis (disappearance of pyuria in absence of infection, significant increase of serum albumin and improvement of renal function tests) \hyperref[b20]{(21)}.\par In case of steroid dependency or steroid refractory TNF-alpha blockers are an effective treatment to induce and maintain remission. The role TNFalpha plays in SLE is controversial and data on the likely effects of blocking TNFalpha on anti-DNA autoantibody production is always of interest. But those antibodies are not generally associated with clinical signs of autoimmunity and there is no indication for monitoring in patients who have no symptoms. There is no clear explanation for this high prevalence of those autoantibodies \hyperref[b21]{(22)}\hyperref[b22]{(23)}\hyperref[b23]{(24)}\hyperref[b24]{(25)}.\par There are, however, occasional reports describing the efficacy of anti-TNF-? therapy for SLE. It has also been reported that, despite levels of antibodies to ds-DNA and cardiolipin being increased, anti-TNF-? therapy did not exacerbate SLE itself but rather achieved a reduction in disease activity and relief of refractory arthritis, nephritis \hyperref[b25]{(26)}.\par TNF-? exerts both deleterious tissue damaging effects mainly through its pro-inflammatory activities and beneficial activities by dampening aggressive autoimmune responses. SLE is a disease with autoimmune disturbance and inflammatory damage, so blocking TNF-? in this autoimmune-prone chronic inflammatory disease may lead to different outcomes, depending on timing and duration of treatment. Thus, infliximabmay also be effective for gastrointestinal symptoms associated with SLE \hyperref[b26]{(27)}.\par To review our therapeutic options we have to define what an immunomodulator refractory colitis is, and search for possible efficient treatment.\par Immunomodulator refractory colitis: Patients who have active disease or relapse in spite of thiopurines at an appropriate dose for at least 3 months (i.e. azathioprine 2-2.5 mg/kg/day or mercaptopurine 0.75-1 mg/kg/day in the absence of leukopenia) \hyperref[b27]{(28)}.\par Different trials report the benefit of methotrexate and tacrolimus in maintaining remission in UC as second-line immunomodulator Therapies. \hyperref[b27]{(28)} The new Zealand society of gastroenterology (28)recommends methotrexate 25 mg weekly for maintaining remission in UC and should be discussed with patients, particularly for those who are steroid dependent.\par However, due to the absence of larger, randomised, controlled trials with lengthy follow-up periods tacrolimus cannot yet be considered standard second-line immunosuppression for UC \hyperref[b27]{(28)}.\par The American college of gastroenterology recommends using anti-TNF therapy using adalimumab, golimumab, or infliximab to maintain remission in patients with previously moderately to severely active UC \hyperref[b8]{(9)}.\par Other therapies have been proposed as an alternative to anti TNF alpha therapy, for patients who are intolerant or who are not responding to it \hyperref[b8]{(9)}.\par Vedolizumab is a monoclonal antibody that selectively blocks ?4?7 integrin expressed on lymphocytes. A phase III trial investigated the induction and maintenance efficacy of vedolizumab in 895 patients with moderate to severe treatment refractory UC. The study revealed clinical remission rates at week 52 of 44.8\% for 4 weekly treatments compared to 15.9\% for placebo p<0.0001.\par Vedolizumab has beed approved by FDA in 2014, and also in many European countries, for the management of moderate to severe UC \hyperref[b27]{(28)}.\par Tofacitinib is an oral inhibitor of Janus Kinases (JAK) 1, 2 and 3, resulting in blocking of interleukin 2, 4, 7, 9, 15 and 21 pathways. Patients were randomised to receive twice daily tofacitinib at doses 0.5, 3, 10 and 15 mg and placebo for 8 weeks. Clinical remission rates at 8 weeks of 48\% and 41\% of patients were seen at doses of 10 mg (p<0.001) and 15 mg (p<0.001) respectively compared to the placebo rate of 10\% \hyperref[b27]{(28)}.\par The American college of gastroenterology recommend to facitinib for maintenance of remission in patients with previously moderately to severely active UC now in remission after induction with to facitinib \hyperref[b8]{(9)}.\par Thirty percent of patients with ulcerative colitis will eventually come to proctocolectomy and this includes some with troublesome distal colitis. The decision as to whether to proceed to surgery is obviously a big one, with life-long consequences \hyperref[b27]{(28)}.\par Removing the colon and rectum in poorly controlled ulcerative colitis restores physical well-being and quality of life \hyperref[b27]{(28)}.\par Long-term concerns about neoplasia are put aside. Patients are understandably very concerned about avoiding a "bag". However the starting point of a discussion with the patient about surgery should focus on whether or not the time has come to remove the colon and rectum.\par Surgery provides a cure for the colitis, but carries a risk of a variety of short-and long-term complications \hyperref[b27]{(28)}.\par There is significant potential for morbidity, but overall greater than 90\% of patients are pleased with their resulting health state and bowel function \hyperref[b28]{(29)}.\par If optimisation of standard immunosuppression fails in mild to moderate UC, then the main therapeutic options currently available are antiTNF-? therapy and colectomy. While other immunosuppressive strategies exist, they have not been demonstrated to have the same efficacy as antiTNF-? therapy and surgery \hyperref[b27]{(28)}.\par To summarize it all, Patients treated for UC as well as SLE can be treated by chloroquine and corticosteroid associated with systemic 5-ASA or immunosuppressive therapy such as azathioprine or 6MP. However, in cases like ours, when the UC is Immunomodulator refractory, treatment to maintain remission can be a real challenge despite different possible options, and differs depending on centers, hospital experience, economic situation as well as patients background.\par IV. \section[{Conclusion}]{Conclusion}\par In conclusion, the diagnostic criteria for UC and SLE overlap, making them difficult to diagnose correctly. Physicians should bear in mind the possibility that a patient may be afflicted with both of these diseases simultaneously. If a patient known to have SLE develops gastrointestinal symptoms such as abdominal pain or diarrhea, it is prudent to rule out UC \hyperref[b29]{(30)}.\par Despite some obscure aspects, our case report suggests that the series of UC associated complaints could include a wide range of autoimmune disorders besides those which have been conventionally considered until now. Therefore, a more accurate detection of autoimmune diseases could be suggested in the diagnostic program to be performed in the course of UC \hyperref[b20]{(21)}.\begin{figure}[htbp] \noindent\textbf{1}\includegraphics[]{image-2.png} \caption{\label{fig_0}Figure 1 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{2}\includegraphics[]{image-3.png} \caption{\label{fig_1}Figure 2 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{34}\includegraphics[]{image-4.png} \caption{\label{fig_2}Figure 3 Figure 4}\end{figure} \begin{figure}[htbp] \noindent\textbf{5}\includegraphics[]{image-5.png} \caption{\label{fig_3}Figure 5}\end{figure} \begin{figure}[htbp] \noindent\textbf{616}\includegraphics[]{image-6.png} \caption{\label{fig_4}Figure 6 Figure 1 - 6 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{7}\includegraphics[]{image-7.png} \caption{\label{fig_5}Figure 7 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{8}\includegraphics[]{image-8.png} \caption{\label{fig_6}Figure 8 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{9}\includegraphics[]{image-9.png} \caption{\label{fig_7}Figure 9 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{10}\includegraphics[]{image-10.png} \caption{\label{fig_8}Figure 10 :}\end{figure} \backmatter \begin{bibitemlist}{1} \bibitem[Amelia and Supriono ()]{b5}\label{b5} ‘17 Year Old Female Patient with Systemic Lupus Erythematosus and Ulcerative Colitis’. R Amelia , S Supriono . \textit{Indones J Gastroenterol Hepatol Dig Endosc} 2014. 15 (1) p. . \bibitem[Rubin et al. ()]{b8}\label{b8} ‘ACG clinical guideline: ulcerative colitis in adults’. D T Rubin , A N Ananthakrishnan , C A Siegel , B G Sauer , M D Long . \textit{Am J Gastroenterol} 2019. 114 (3) p. . \bibitem[Zhu et al. ()]{b26}\label{b26} ‘Anti-TNF-? Therapies in Systemic Lupus Erythematosus’. L-J Zhu , X Yang , X-Q Yu . \url{https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2896679/} \textit{J Biomed Biotechnol} 2010. (Internet. cité 18 oct 2020]; 2010. Disponible sur) \bibitem[Koutroubakis et al. ()]{b4}\label{b4} ‘Association between ulcerative colitis and systemic lupus erythematosus: report of two cases’. I E Koutroubakis , H Kritikos , I A Mouzas , S M Spanoudakis , A N Kapsoritakis , E Petinaki . \textit{Eur J Gastroenterol Hepatol} 1998. 10 (5) p. . \bibitem[Subramanian et al. ()]{b18}\label{b18} ‘Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent’. S Subramanian , V Yajnik , B E Sands , G Cullen , J R Korzenik . \textit{Inflamm Bowel Dis} 2011. 17 (1) p. . \bibitem[Garcia-Planella et al. ()]{b22}\label{b22} ‘Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNF? antibodies (infliximab)’. E Garcia-Planella , E Domènech , M Esteve-Comas , I Bernal , E Cabré , J Boix . \textit{Eur J Gastroenterol Hepatol} 2003. 15 (4) p. . \bibitem[Vedove et al. ()]{b15}\label{b15} ‘Drug-induced lupus erythematosus’. Dalle Vedove , C , Del Giglio , M Schena , D Girolomoni , G . \textit{Arch Dermatol Res} 2009. 301 (1) p. . \bibitem[Vaglio et al. ()]{b16}\label{b16} ‘Drug-induced lupus: Traditional and new concepts’. A Vaglio , P C Grayson , P Fenaroli , D Gianfreda , V Boccaletti , G M Ghiggeri . \textit{Autoimmun Rev} 2018. 17 (9) p. . \bibitem[Tian and Zhang ()]{b13}\label{b13} ‘Gastrointestinal involvement in systemic lupus erythematosus: insight into pathogenesis, diagnosis and treatment’. X-P Tian , X Zhang . \textit{World J Gastroenterol WJG} 2010. 16 (24) p. 2971. \bibitem[Wallace ()]{b11}\label{b11} ‘Gastrointestinal manifestations and related liver and biliary disorders’. D J Wallace . \textit{Dubois' Lupus Erythematosus} 1993. 42 p. . \bibitem[Hallegua and Wallace ()]{b10}\label{b10} ‘Gastrointestinal manifestations of systemic lupus erythematosus’. D S Hallegua , D J Wallace . \textit{Curr Opin Rheumatol} 2000. 12 (5) p. . \bibitem[Koutroubakis and Pena ()]{b6}\label{b6} ‘Genetics of inflammatory bowel disease’. I Koutroubakis , A S Pena . \textit{Inflamm Bowel Dis} 1997. Ed N Y Churchill Livingstone. 3 p. . \bibitem[Fazio et al. ()]{b28}\label{b28} ‘Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients’. V W Fazio , R P Kiran , F H Remzi , J C Coffey , H M Heneghan , H T Kirat . \textit{Ann Surg. avr} 2013. 257 (4) p. . \bibitem[Katsanos et al. ()]{b24}\label{b24} ‘Inflammatory bowel disease and lupus: a systematic review of the literature’. K H Katsanos , P V Voulgari , E V Tsianos . \textit{J Crohns Colitis} 2012. 6 (7) p. . \bibitem[Rutgeerts et al. ()]{b21}\label{b21} ‘Infliximab for induction and maintenance therapy for ulcerative colitis’. P Rutgeerts , W J Sandborn , B G Feagan , W Reinisch , A Olson , J Johanns . \textit{N Engl J Med} 2005. 353 (23) p. . \bibitem[Principi et al. ()]{b20}\label{b20} ‘Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn's disease: a case report’. M Principi , Di Leo , A Ingrosso , M Pisani , A Marangi , S Amoruso , A . \textit{Immunopharmacol Immunotoxicol} 2004. 26 (2) p. . \bibitem[Eliadou et al. ()]{b27}\label{b27} ‘New Zealand Society of Gastroenterology Guidelines for the Management of Refractory Ulcerative Colitis’. E Eliadou , A S Day , M W Thompson-Fawcett , R B Gearry , D S Rowbotham , R Walmsley . \textit{N Z Med J} 16 oct 2015. 1423. 128 p. . \bibitem[Aringer et al. ()]{b25}\label{b25} ‘Safety and efficacy of tumor necrosis factor ? blockade in systemic lupus erythematosus: An open-label study’. M Aringer , W B Graninger , G Steiner , J S Smolen . \textit{Arthritis Rheum Off J Am Coll Rheumatol} 2004. 50 (10) p. . \bibitem[Griffiths and Kane ()]{b17}\label{b17} ‘Sulphasalazine-induced lupus syndrome in ulcerative colitis’. I D Griffiths , S P Kane . \textit{Br Med J} 1977. 2 (6096) p. 1188. \bibitem[Batchelor ()]{b7}\label{b7} ‘Systemic lupus erythematosus and genes within the HLA region’. J R Batchelor . \textit{Rheumatology} 1993. 32 (1) p. . \bibitem[Nitzan et al. ()]{b14}\label{b14} ‘Systemic lupus erythematosus and inflammatory bowel disease’. O Nitzan , M Elias , W R Saliba . \textit{Eur J Intern Med} 2006. 17 (5) p. . \bibitem[Font et al. ()]{b3}\label{b3} ‘Systemic lupus erythematosus and ulcerative colitis’. J Font , X Bosch , J Ferrer , F Pérez-Villa , M Ingelmo . \textit{The Lancet} 1988. 331 (8588) p. 770. \bibitem[Medeiros and Isenberg ()]{b9}\label{b9} ‘Systemic lupus erythematosus and ulcerative colitis’. D A Medeiros , D A Isenberg . \textit{Lupus} 2009. 18 (8) p. 762. \bibitem[Yamashita et al. ()]{b19}\label{b19} ‘Systemic lupus erythematosus complicated by Crohn's disease: a case report and literature review’. H Yamashita , Y Ueda , H Kawaguchi , A Suzuki , Y Takahashi , H Kaneko . \textit{BMC Gastroenterol} 2012. 12 (1) p. 174. \bibitem[Stevens and Ostlere ()]{b0}\label{b0} ‘Systemic lupus erythematosus in association with ulcerative colitis: related autoimmune diseases’. H P Stevens , L S Ostlere , RustinMha . \textit{Br J Dermatol} 1994. 130 (3) p. . \bibitem[Mansour et al. ()]{b2}\label{b2} ‘Systemic lupus erythematosus with inflammatory bowel disease-ulcerative colitis: case report’. H E Mansour , S G Arafa , W A Shehata . \textit{Lupus} 2018. 27 (7) p. . \bibitem[Hoffman and Katz ()]{b12}\label{b12} ‘The gastrointestinal manifestations of systemic lupus erythematosus: a review of the literature’. B I Hoffman , W A Katz . \textit{Seminars in arthritis and rheumatism}, 1980. WB Saunders. p. . \bibitem[Mageed and Isenberg ()]{b23}\label{b23} ‘Tumour necrosis factor alpha in systemic lupus erythematosus and anti-DNA autoantibody production’. R A Mageed , D A Isenberg . \textit{Lupus} 2002. 11 (12) p. . \bibitem[Oussama et al. ()]{b29}\label{b29} ‘Ulcerative Colitis and Systemic Lupus Erythematosus: An Unusual Association with Diagnostic and Therapeutic Difficulties’. N Oussama , A Fatimaezzahra , A Adil , S Zouhour , K Khadija , O Sofia . \textit{Sch J Appl Med Sci. 25 janv} 2020. 08 (01) p. . \bibitem[Ishikawa et al. ()]{b1}\label{b1} ‘Ulcerative colitis associated with preceding systemic lupus erythematosus’. O Ishikawa , Y Miyachi , K Fujita , S Takenoshita , Y Nagamachi , J Hirato . \textit{J Dermatol} 1995. 22 (4) p. . \end{bibitemlist} \end{document}